전화상담 : 1588-7309
28 06, 2018

히드록시진(Hydroxyzine)

By | 18년 6월 28일|다빈도 노출약물|0 Comments

▪ 약물의 분류: 항히스타민제 ▪ 임신부 약물등급(US FDA): C ▪ 임신부 안전 및 기형발생정보: Hydroxyzine produced adverse pregnancy effects in rodents. There is limited published experience during human pregnancy. ▪ 모유수유부 약물등급(Medication and Mother’s MilK): L2 ▪ 모유수유 안전 및 유해성정보: The product labeling for hydroxyzine suggests that it be avoided by nursing mothers because [...]

28 06, 2018

하이드로코르티손(Hydrocortisone)

By | 18년 6월 28일|다빈도 노출약물|0 Comments

▪ 약물의 분류: 진통제 ▪ 임신부 약물등급(US FDA): C ▪ 임신부 안전 및 기형발생정보: Cortisol (hydrocortisone) is a naturally occurring glucocorticoid. Glucocorticoid medication use during pregnancy has been associated with an increased risk of cleft palate and impaired fetal growth. Cortisol may be used during nursing. ▪ 모유수유부 약물등급(Medication and Mother’s MilK): L3 ▪ 모유수유 [...]

28 06, 2018

피프린히드리네이트(Piprinhydrinate)

By | 18년 6월 28일|다빈도 노출약물|0 Comments

▪ 약물의 분류: 항히스타민제 ▪ 임신부 약물등급(US FDA): 정보없음 ▪ 임신부 안전 및 기형발생정보: 정보없음 ▪ 모유수유부 약물등급(Medication and Mother’s MilK): 정보없음 ▪ 모유수유 안전 및 유해성정보: 정보없음 ▪ 한국마더세이프전문상담센터 DB 정보 (모태독성학2016): 1) 기형발생정보 피프린히드리네이트에 노출된 후 추적된 임신부는 총 154례이었으며 초기 노출 후 자연유산율은 5.8%(9/154)이었다. 임신 37주 이전의 조산률은 5.6%(8/144), 2,500 g 미만의 [...]

28 06, 2018

플루옥세틴(Fluoxetine)

By | 18년 6월 28일|다빈도 노출약물|0 Comments

▪ 약물의 분류: 항우울제(SSRI, selective serotonin reuptake inhibitor) ▪ 임신부 약물등급(US FDA): C ▪ 임신부 안전 및 기형발생정보: Based on experimental animal studies and human experience, fluoxetine is not expected to increase the risk of major congenital anomalies. Human studies have inconsistently reported associations of fluoxetine use during pregnancy and heart defects in the offspring. [...]

28 06, 2018

프레드니손/프레드니솔론(Prednisone/Prednisolone)

By | 18년 6월 28일|다빈도 노출약물|0 Comments

▪ 약물의 분류: 면역억제제 ▪ 임신부 약물등급(US FDA): C ▪ 임신부 안전 및 기형발생정보 : Prednisone can be associated with fetal growth impairment in humans. Some glucocorticoids increase oral clefting in experimental animals and might do so in humans as well. ▪ 모유수유부 약물등급(Medication and Mother’s MilK): L2 ▪ 모유수유 안전 및 유해성정보 : When [...]

28 06, 2018

펜디메트라진(Phendimetrazine)

By | 18년 6월 28일|다빈도 노출약물|0 Comments

▪ 약물의 분류: 식욕억제제 ▪ 임신부 약물등급(US FDA): C ▪ 임신부 안전 및 기형발생정보 : There are no data on possible pregnancy effects of phendimetrazine. Phenmetrazine, a similar drug, has been used during pregnancy without apparent adverse effect; however, weight loss is not recommended during pregnancy. ▪ 모유수유부 약물등급(Medication and Mother’s MilK): 정보없음 ▪ 모유수유 [...]

28 06, 2018

펙소페나딘(Fexofenadine)

By | 18년 6월 28일|다빈도 노출약물|0 Comments

▪ 약물의 분류: 항히스타민제 ▪ 임신부 약물등급(US FDA): C ▪ 임신부 안전 및 기형발생정보 : Based on experimental animal studies (and human reports for the parent compound, terfenadine), fexofenadine exposure during pregnancy is not expected to increase the risk of adverse outcome. ▪ 모유수유부 약물등급(Medication and Mother’s MilK): L2 ▪ 모유수유 안전 및 유해성정보 : [...]

28 06, 2018

페닐프로파놀라민(Phenylpropanolamine)

By | 18년 6월 28일|다빈도 노출약물|0 Comments

▪ 약물의 분류: 교감신경흥분제 ▪ 임신부 약물등급(US FDA): 정보없음 ▪ 임신부 안전 및 기형발생정보 Phenylpropanolamine is avoided during pregnancy because of its vasoconstrictive activity and findings in some case-control studies suggestive of a small increase in unusual birth defects including gastroschisis and hemifacial microsomia with agents that constrict blood vessels. Causation has not been established [...]

28 06, 2018

페닐에프린(Phenylephrine)

By | 18년 6월 28일|다빈도 노출약물|0 Comments

▪ 약물의 분류: 충혈완화제, 교감신경흥분제 ▪ 임신부 약물등급(US FDA): C ▪ 임신부 안전 및 기형발생정보 Phenylephrine is avoided during pregnancy because of its vasoconstrictive activity and findings in some case-control studies suggestive of a small increase in gastroschisis and hemifacial microsomia with agents that constrict blood vessels. Causation has not been established by these studies. [...]

28 06, 2018

판크레아틴(Pancreatin: pancrelipase)

By | 18년 6월 28일|다빈도 노출약물|0 Comments

▪ 약물의 분류: 건위소화제 ▪ 임신부 약물등급(US FDA): C ▪ 임신부 안전 및 기형발생정보 Pancreatin (Ilozyme) is an animal pancreatic extract containing digestive enzymes and used as a digestive aid. The Collaborative Perinatal Project did not find an association between pancreatin use and an increase in adverse pregnancy outcome. According to a report prepared by [...]